Company: XTIA
Filing Date: 2025-11-21
Form Type: PRER14A
Source: 0001213900-25-113701
Chunk: 14

Company: XTI Aerospace, Inc.
Filing Date: 2025-11-21
Form: PRER14A
Chunk 14
---
lying Shares or (ii)
the date on which the Underlying Shares may be sold without restriction, including volume or manner-of-sale restrictions, pursuant to
Rule 144.

From the date of the PIPE
Purchase Agreement until the later of the date that is 5 days from the date (a) Shareholder Approval is obtained and (b) the date that
the Registration Statement has been declared effective by the Commission, the Company agreed to not enter into any transaction for the
sale of any of its equity securities or securities convertible into its equity securities unless the price per share of the Company’s
common stock or per unit price (or conversion price or exercise price, as applicable) is equal to or greater than $2.50, subject to certain
customary exempt issuance exceptions.

The Series 10 Preferred
Stock has no voting rights, except as required by law and for certain customary protective provisions set forth in the Certificate of
Designation.

Upon any liquidation, dissolution
or winding-up of the Company (but excluding a Fundamental Transaction), whether voluntary or involuntary, the holders of the Series 10
Preferred Stock are entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the Stated Value,
plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under the Certificate
of Designation, for each share of Series 10 Preferred Stock before any distribution or payment is made to the holders of any Junior Securities.

ThinkEquity served as placement
agent and received $1,750,000 of placement agent fees and warrants to purchase 837,801 shares of common stock, which were exercisable
commencing November 12, 2025, expire November 12, 2030 and have an exercise price of $1.492 per share. The Company’s obligation
to issue shares upon exercise of the placement agent warrants is subject to the Company’s receipt of Shareholder Approval. Pursuant
to the terms of the placement agent warrants, if the holder exercises such warrants prior to the Shareholder Approval Date, the holder
will receive the right to receive on the Shareholder Approval Date the number of shares so issuable upon such exercise and, on the Shareholder
Approval Date, the Company will issue such shares to the holder in accordance with this the terms of the placement agent warrants. Pursuant
to the terms of the placement agent warrants, the Company is obligated to use its commercially reasonable efforts to solicit the Shareholder